Document is current
Any future updates will be listed below
-
Authors
Bais, Thomas
Meijer, Esther http://orcid.org/0000-0001-7875-1793
Kramers, Bart J.
Vart, Priya
Vervloet, Marc
Salih, Mahdi
Bammens, Bert
Demoulin, Nathalie
Todorova, Polina
Müller, Roman-Ulrich
Halbritter, Jan
Paliege, Alexander
Gall, Emilie Cornec-Le
Knebelmann, Bertrand
Torra, Roser
Ong, Albert C. M.
Karet Frankl, Fiona E.
Gansevoort, Ron T.
-
Funding
Funding for this research was provided by:
ZonMW (10140022010010)
Otsuka Pharmaceutical (102344)
- License Information
-
More Information
Article History
Received: 18 July 2023
Accepted: 24 January 2024
First Online: 14 February 2024
Declarations
:
: Institutional Review Board approval was obtained to conduct the clinical trial in the participating countries. This trial will be conducted in accordance with the International Conference of Harmonization Good Clinical Practice Guidelines and will adhere to the ethical principles that have their origin in the Declaration of Helsinki. Informed consent is obtained by the local principal investigator or a delegated member of the study team. Collection and use of biological material and data for ancillary studies require additional (optional) consent provisions. All participants have the right to withdraw at any time during the study. Important protocol modifications are communicated to all relevant parties, including investigators, IRBs, trial participants, regulators, and trial registries. The model consent form is available as InternalRef removed.
: Not applicable
: EM received consultancy fees from Otsuka and research funding from Sanofi and the Dutch Kidney Foundation. RG received consultancy fees and/or research grants from Astra-Zeneca, Bayer, Boehringer-Ingelheim, Galapagos, Ipsen, Mironid, Otsuka, and Sanofi. All money was paid to the institution. AP received research funding and lecture fees from Otsuka. The other authors declare that they have no competing interests.
